Over 16 million Americans suffer from chronic obstructive pulmonary disease, or COPD. 1 COPD makes it hard to breathe, and can also cause wheezing, coughing, and chest tightness. When COPD flares up, it can be quite scary, and your breathing can become extremely difficult. While medications can help, they do not always effectively control these flare-ups.2,3
If you have COPD and still experience flare-ups despite your medications, you may qualify for the AIRFLOW-3 Clinical Trial. The trial is evaluating Targeted Lung Denervation, a one-hour, investigational treatment that targets problems in the airways and may reduce the risk of future flare-ups.
What is Targeted Lung Denervation (TLD)?
People with COPD have overactive nerves in their airways. This can lead to symptoms and flare-ups that can range from mild, moderate or severe. COPD flare-ups can further damage your lungs, making it difficult to recover to your ‘normal’ symptom levels. While medications can help with COPD, they do not always control these flare-ups.2,3
The dNerva® Lung Denervation System is a new investigational device used in a non-surgical procedure called Targeted Lung Denervation, or TLD. The procedure is designed to reduce airway nerve activity, which may potentially reduce the risk of COPD flare-ups.
How does it work?
The dNerva Lung Denervation System and TLD procedure is currently being offered at select US study centers through the AIRFLOW-3 Clinical Trial.
Why should I participate?
COPD treatment is changing
Medical device research, like this study, are critical to advancing healthcare. Your participation will help us get closer to finding a solution and bringing new treatments and therapies to more people with COPD.
If you qualify, your treatment and care will all be delivered at no cost to you.
If you qualify and choose to join the study, you will receive:
See If You Qualify
To see if you might qualify for the AIRFLOW-3 Clinical Trial, and to get connected with your local study center to learn more, please take the questionnaire below.
Common potential risks associated with the TLD procedure include, but are not limited to, worsening of COPD symptoms (shortness of breath, increased cough, COPD exacerbations), coughing up blood tinged mucous, difficulty swallowing, chest pain, upset stomach or feeling of fullness, trouble processing food, and fever.
Nuvaira® Lung Denervation System is an investigational device in the United States and has CE mark regulatory approval in the European Economic Area (EEA).
A flare-up is a worsening of COPD symptoms that require additional medications to treat and can also result in visits to the emergency room, visits to a doctor, or hospitalization.